Pfizer (FRA:PFE) Cyclically Adjusted PS Ratio: (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PFE Pfizer Inc FRA:PFE
66 GF Score
Price €22.06
GF Value €22.43
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pfizer  (FRA:PFE) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Pfizer Cyclically Adjusted PS Ratio Related Terms


Pfizer Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Pfizer's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Cyclically Adjusted PS Ratio Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.29 4.74 2.56 2.28 2.07

Pfizer Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.03 2.12 2.07 2.30 0.00

FRA:PFE vs BMY, GILD, AMGN: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted PS Ratio falls into.


FRA:PFE
66GF Score
Pfizer Inc FRA:PFE
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Pfizer's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Pfizer's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.29/333.9520*333.9520
=2.290

Current CPI (Jun. 2026) = 333.9520.

Pfizer Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.890 241.428 2.614
201612 2.114 241.432 2.924
201703 1.961 243.801 2.686
201706 1.901 244.955 2.592
201709 1.829 246.819 2.475
201712 1.910 246.524 2.587
201803 1.728 249.554 2.312
201806 1.937 251.989 2.567
201809 1.904 252.439 2.519
201812 0.172 251.233 0.229
201903 2.019 254.202 2.652
201906 2.070 256.143 2.699
201909 2.038 256.759 2.651
201912 0.295 256.974 0.383
202003 1.626 258.115 2.104
202006 1.559 257.797 2.020
202009 1.549 260.280 1.987
202012 1.659 260.474 2.127
202103 2.154 264.877 2.716
202106 2.763 271.696 3.396
202109 3.569 274.310 4.345
202112 3.658 278.802 4.382
202203 4.047 287.504 4.701
202206 4.595 296.311 5.179
202209 3.999 296.808 4.499
202212 4.130 296.797 4.647
202303 3.015 301.836 3.336
202306 2.101 305.109 2.300
202309 2.239 307.789 2.429
202312 2.346 306.746 2.554
202403 2.403 312.332 2.569
202406 2.166 314.175 2.302
202409 2.796 315.301 2.961
202412 2.975 315.605 3.148
202503 2.222 319.799 2.320
202506 2.226 322.561 2.305
202509 2.483 324.800 2.553
202512 2.620 324.054 2.700
202603 2.181 330.213 2.206
202606 2.290 333.952 2.290

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Pfizer (FRA:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of €22.06 is trading 1.6% below its estimated GF Value™ of €22.43. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for FRA:PFE:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €22.43 vs. price of €22.06 (1.6% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the FRA:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
66GF Score

Get the complete analysis for FRA:PFE

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.06
Price
€22.43
GF Value